Inovio Pharmaceuticals Inc. (INO)

3.71
0.04 1.07
NASDAQ : Health Technology
Prev Close 3.75
Open 3.77
Day Low/High 3.70 / 3.92
52 Wk Low/High 3.63 / 6.30
Volume 1.83M
Avg Volume 891.30K
Exchange NASDAQ
Shares Outstanding 95.35M
Market Cap 351.83M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Inovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering

Inovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering

PLYMOUTH MEETING, Pa., Feb.

Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

PLYMOUTH MEETING, Pa., Feb.

INO Crosses Below Key Moving Average Level

INO Crosses Below Key Moving Average Level

In trading on Tuesday, shares of Inovio Pharmaceuticals Inc. crossed below their 200 day moving average of $4.77, changing hands as low as $4.72 per share.

Inovio's DMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher And More Prolonged Expression Compared To Native Pembrolizumab And Nivolumab Sequences In Preclinical Studies

Inovio's DMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher And More Prolonged Expression Compared To Native Pembrolizumab And Nivolumab Sequences In Preclinical Studies

PD-1 DNA-encoded monoclonal antibodies (dMAbs) highlighted in a paper published in cancer journal Oncotarget

Inovio Pharmaceuticals (INO) Shares Cross Above 200 DMA

Inovio Pharmaceuticals (INO) Shares Cross Above 200 DMA

In trading on Monday, shares of Inovio Pharmaceuticals Inc. crossed above their 200 day moving average of $4.76, changing hands as high as $4.96 per share.

Inovio's DNA-Encoded Monoclonal Antibody (dMAb™) Platform Leaps Forward With First-in-Human Trial

Inovio's DNA-Encoded Monoclonal Antibody (dMAb™) Platform Leaps Forward With First-in-Human Trial

First Human dMAb Study Will Target Zika Infection

Interesting INO Put And Call Options For August 16th

Interesting INO Put And Call Options For August 16th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the August 16th expiration.

Inovio Announces Appointments To Its Board Of Directors

Inovio Announces Appointments To Its Board Of Directors

Simon X. Benito, Director Since 2003, Named Chairman of the Board; Lota Zoth, former MedImmune CFO, Joins Board

Interesting INO Put And Call Options For October 19th

Interesting INO Put And Call Options For October 19th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the October 19th expiration.

Bullish Two Hundred Day Moving Average Cross - INO

Bullish Two Hundred Day Moving Average Cross - INO

In trading on Tuesday, shares of Inovio Pharmaceuticals Inc. crossed above their 200 day moving average of $4.51, changing hands as high as $4.54 per share.

Interesting INO Put And Call Options For February 2019

Interesting INO Put And Call Options For February 2019

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the February 2019 expiration.

First Week Of July 20th Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the July 20th expiration.

Interesting INO Call Options For June 15th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the June 15th expiration.

Exiting Position With a Nice Profit

We are selling all of our shares of Marrone Bio Innovations, as news of common offering changes the game for us.

Inovio Closes License And Collaboration Agreement with ApolloBio To Develop And Commercialize VGX-3100 In Greater China

Inovio Closes License And Collaboration Agreement with ApolloBio To Develop And Commercialize VGX-3100 In Greater China

Inovio will immediately receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on future sales

Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

INO-1800 shows ability to activate and expand CD8+ killer T cells

Two Exits and an Initiation

We’re cleaning house of Three-rated Inovio Pharma and Pixelworks and starting a small position in ancillary cannabis play Kush Bottles.

Inovio Pharmaceuticals Stock Sees Short Interest Increase 13%

Inovio Pharmaceuticals Stock Sees Short Interest Increase 13%

The most recent short interest data has been released for the 02/15/2018 settlement date, which shows a 1,234,538 share increase in total short interest for Inovio Pharmaceuticals Inc. , to 10,650,607, an increase of 13.11% since 01/31/2018.

Stocks Under $10 Weekly Summary

During a shortened trading week we closed out of one position and added to another after earnings reports.

First Week of April 20th Options Trading For Inovio Pharmaceuticals (INO)

First Week of April 20th Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the April 20th expiration.

Stocks Under $10 Weekly Summary

We shed two positions last week as the market roared back.

Stocks Under $10 Weekly Summary

We added to several positions on weakness during a challenging last week for the stock market.

Stocks Under $10 Weekly Summary

We exited one position and added to another as volatility returned to the stock market last week.

TheStreet Quant Rating: D (Sell)